Skip to content

Comparison between intravenous Calcium Chloride vs only Oxytocin in decreasing blood loss during cesarean delivery

A Randomized Controlled Trial on Administration of intravenous Calcium Chloride in addition to routine Oxytocin in reducing blood loss during cesarean section - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/090730
Enrollment
66
Registered
2025-07-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O678- Other intrapartum hemorrhage

Interventions

Intervention1: Iv Calcium chloride: Receive IV calcium chloride (10% solution, 1 g) during cesarean section through iv route over 10 minutes along with the routine administration of oxytocin (10-20 un

Sponsors

Varsha Rani
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Women aged 18-40 years. b) Women who underwent elective or emergency cesarean section at the study institution. c) Singleton pregnancies with no known placental or uterine abnormalities. d) Women who received either IV calcium chloride with oxytocin (group 1) or only oxytocin (group 2) as part of routine clinical management.

Exclusion criteria

Exclusion criteria: a) Women with known allergies or contraindications to calcium chloride. b) Women with pre-existing cardiac arrhythmias or significant cardiovascular disease. c) Women with pre-existing coagulopathies or those who are on anticoagulant therapy. d) Women with uterine anomalies, placenta previa, or other conditions that may confound blood loss. e) Women who had a hysterectomy or other major surgical interventions during the cesarean.

Design outcomes

Primary

MeasureTime frame
Total blood loss during cesarean section as measured by the volume of blood collected in suction containers and the weight of surgical sponges (considering 1 g of weight = 1 mL of blood).Timepoint: 18 monnths

Secondary

MeasureTime frame
Need for blood transfusion due to excessive blood loss (if applicable). Timepoint: 18 months;Uterine tone post-delivery (evaluated by the obstetrician). Timepoint: 18 months;Incidence of uterine atony, requiring additional uterotonic drugs. Timepoint: 18 months;Maternal complications: Hypotension, arrhythmias, or hypercalcemia. Timepoint: 18 months;Length of hospital stay and recovery outcomes. Timepoint: 18 months

Countries

India

Contacts

Public ContactDr Avir Sarkar

AIIMS Kalyani

avir.obg@aiimskalyani.edu.in6280765384

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026